Lannett Company, Inc. (LCI)
Seite 1 von 3 Neuester Beitrag: 21.04.23 15:45 | ||||
| Eröffnet am: | 05.08.17 02:38 | von: Chalifmann3 | Anzahl Beiträge: | 63 |
| Neuester Beitrag: | 21.04.23 15:45 | von: Vassago | Leser gesamt: | 20.220 |
| Forum: | Hot-Stocks | Leser heute: | 2 | |
| Bewertet mit: |  | |||
| Seite: < 1 | 2 | 3 > | ||||
Lannett Company, Inc. develops, manufactures, packages, markets, and distributes generic versions of brand pharmaceutical products in the United States. It offers solid oral, extended release, topical, nasal, and oral solution finished dosage forms of drugs that address a range of therapeutic areas, as well as ophthalmic, patch, foam, buccal, sublingual, soft gel, and injectable dosages. The company provides its products for various medical indications comprising glaucoma, muscle relaxant, migraine, anesthetic, congestive heart failure, gastrointestinal, cardiovascular, thyroid deficiency, central nervous system, urinary, dryness of the mouth, gout, hypertension, and gallstone. It also manufactures active pharmaceutical ingredients. Lannett Company, Inc. markets its products under the Diamox, Fioricet, Fiorinal, Lanoxin, MiraLAX, Imdur, Levoxyl/Synthroid, Metadate CD, Concerta, Procardia, Prilosec, Ditropan, Protonix, Salagen, Dyazide, and Actigall brands. The company sells its pharmaceutical products to generic pharmaceutical distributors, drug wholesalers, chain drug retailers, private label distributors, mail-order pharmacies, other pharmaceutical manufacturers, managed care organizations, hospital buying groups, governmental entities, and health maintenance organizations. The company has supply and development agreements with JSP, Summit Bioscience LLC, HEC Pharm Group, and Pharma Pass II LLC. Lannett Company, Inc. was founded in 1942 and is based in Philadelphia, Pennsylvania.
Optionen
| Boardmail an "Chalifmann3" |
Wertpapier: Lannett |
Optionen
| Boardmail an "stereotyp72" |
Wertpapier: Lannett |
schlechte Nachrichten
- ~ 340 Mio. $ Goodwill Abschreibungen im September-Quartal 2018
- Lannett lässt Schulden- und Kapitalstrukturalternativen prüfen
https://seekingalpha.com/news/3395621-lannett-write-340m-goodwill-fq1
http://lannett.investorroom.com/...And-Capital-Structure-Alternatives
Optionen
| Boardmail an "Vassago" |
Wertpapier: Lannett |
Lannett meldet Ergebnisse für das September-Quartal 2018
- Umsatz 155 Mio. $
- Asset Impairment ("Abschreibungen") 369 Mio. $
http://lannett.investorroom.com/...-Adjusted-Guidance-For-Fiscal-2019
Optionen
| Boardmail an "Vassago" |
Wertpapier: Lannett |
Lannett meldet Ergebnisse für das Juni-Quartal 2019
- Umsatz 134 Mio. $ (FY19 ~655 Mio. $)
- Verlust 8 Mio. $ (FY19 ~272 Mio. $)
- Umsatz und adj. Ergebnis allerdings über den Analystenerwartungen
- FY20 Umsatzausblick 525-545 Mio. $
http://lannett.investorroom.com/...ts-Issues-Guidance-For-Fiscal-2020
https://www.fool.com/investing/2019/08/27/...netts-great-q4-resu.aspx
Optionen
| Boardmail an "Vassago" |
Wertpapier: Lannett |
- Umsatzausblick von 520-545 auf 480-500 Mio. $ gesenkt
- Dez-Q Umsatz 134 Mio. $
- adj. Gewinn 3 Mio. $
"During the fiscal 2021 second quarter, the company recorded non-cash, asset impairment charges of $198.0 million, primarily related to the write down of intangible assets associated with the acquisition of Kremers Urban Pharmaceuticals"
https://lannett.investorroom.com/...lts-In-Line-Or-Above-Expectations
Optionen
| Boardmail an "Vassago" |
Wertpapier: Lannett |
Ende Mai ist Lannett aus dem "S&P SmallCap 600"-Index geflogen.
Zahlen für das März-Quartal 2021
- Umsatz 112 Mio. $
- Verlust 7 Mio. $
- Cash 81 Mio. $
- MK 199 Mio. $
"In April, we successfully completed a transaction to refinance our debt, using the proceeds to retire the outstanding Term Loan B balance of approximately $540 million that was set to mature in November of next year. As a result, we have extended the maturity of our debt to 2026 from 2022, which is after several high-value pipeline assets are expected to be commercialized"
https://lannett.investorroom.com/...1-Third-Quarter-Financial-Results
Optionen
| Boardmail an "Vassago" |
Wertpapier: Lannett |
Zahlen für das Juni-Quartal 2021
- Umsatz 106 Mio. $
- Verlust 178 Mio. $
- Cash 93 Mio. $
- MK 169 Mio. $
- FY22 Umsatzausblick 400-440 Mio. $
https://lannett.investorroom.com/...rter,-Full-Year-Financial-Results
Optionen
| Boardmail an "Vassago" |
Wertpapier: Lannett |
Optionen
| Boardmail an "Chalifmann3" |
Wertpapier: Lannett |
das heisst doch die kredite muessen erst 2026 zurueckgezahlt werden,oder ? dann sieht es doch so uebel garnicht aus fuer den Preis ,quasi geschenkt aktuell .....
Optionen
| Boardmail an "Chalifmann3" |
Wertpapier: Lannett |
Zahlen für das März-Quartal 2022
- Umsatz 78 Mio. $
- Verlust 35 Mio. $
- Cash 106 Mio. $
MK 24 Mio. $
https://lannett.investorroom.com/...2-THIRD-QUARTER-FINANCIAL-RESULTS
Meiner Meinung nach ist das eher ein Selbstmordkommando, die verbrennen 35 Mio. $ pro Q und haben 105 Mio. $ an Cash = 3 Quartale Cashreichweite. Mal von den hohen Schulden (>700 Mio. $) ganz abgesehen
Optionen
| Boardmail an "Vassago" |
Wertpapier: Lannett |
Optionen
| Boardmail an "Chalifmann3" |
Wertpapier: Lannett |
NYSE Delistung / OTC Listing
https://lannett.investorroom.com/...ND-COMMENCE-DELISTING-PROCEEDINGS
Optionen
| Boardmail an "Vassago" |
Wertpapier: Lannett |